4//SEC Filing
Rankin Aubrey 4
Accession 0001628280-20-014083
CIK 0001479290other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 9:21 PM ET
Size
7.0 KB
Accession
0001628280-20-014083
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Sale
Common Stock
2020-09-28$26.18/sh−33,119$867,055→ 576,922 total(indirect: By Trust)
Holdings
- 174,302(indirect: By Trust)
Common Stock
- 67,871
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $26.74. Mr. Rankin undertakes to provide to the Issuer,any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
- [F4]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001818576
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 9:21 PM ET
- Size
- 7.0 KB